Focus: Immatics Biotechnologies is a Munich-based biotech specialist in personalized T-cell directed immunotherapies focused on oncology. The company operates as a clinical-stage innovator with a diversified pipeline spanning multiple tumor types.
Profile data last refreshed 47m ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
5 added, 4 removed. Backfill posture.
Best suited for early-career or mission-driven scientists seeking deep immunotherapy expertise in a private, innovation-focused biotech, not for those prioritizing rapid advancement or financial stability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Immatics Biotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Immatics Biotechnologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo